In this issue:
Overall survival with ribociclib plus letrozole in advanced breast cancer
Trastuzumab deruxtecan versus trastuzumab emtansine
Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer
Aromatase inhibitors versus tamoxifen in premenopausal women
Outcomes of breast cancer patients during the COVID-19 pandemic
Efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes
Comparison of StemPrintER with oncotype DX recurrence score
Lobular versus ductal histology on overall survival in metastatic breast cancer
Adverse health effects after breast cancer up to 14 years after diagnosis
The impact of young age on prognosis by breast cancer subtype
Please login below to download this issue (PDF)